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Abstract Recently, there are more and more evidences from
studies have revealed the association between microRNA-9
(miR-9) expression and outcome in multiple cancers, but in-
consistent results have also been reported. It is necessary to
rationalize a meta analysis of all available data to clarify the
prognostic role of miR-9. Eligible studies were selected
through multiple search strategies and the quality was
assessed byMOOSE. Data was extracted from studies accord-
ing to the key statistics index. All analyses were performed
using STATA software. Twenty studies were selected in the
meta-analysis to evaluate the prognostic role of miR-9 in mul-
tiple tumors. MiR-9 expression level was an independent
prognostic biomarker for OS in tumor patients using multivar-
iate and univariate analyses. High expression levels of miR-9
was demonstrated to associated with poor overall survival
(OS) (HR = 2.23, 95 % CI: 1.56–3.17, P < 0.05) and recur-
rence free survival/progress free survival (RFS/PFS) (HR =
2.08, 95 % CI: 1.33–3.27, P < 0.05). Subgroup analysis
showed that residence region (China and Japan), sample size,
cancer type (solid or leukemia), follow-up months and analy-
sis method (qPCR) did not alter the predictive value of miR-9
on OS in various cancers. Furthermore, no significant associ-
ations were detected for miR-9 expression and lymph node
metastasis or distant metastasis. The present results suggest
that promoted miR-9 expression is associated with poor OS
in patients with general cancers.
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Introduction
Cancer is not only the most serious disease but also the leading
cause of death for human health over the past decade [1]. In
2014, an estimated 1,665,540 new cancer cases and 585,720
cancer deaths are projected to occur in the United States [2].
Even though tremendous progresses have been made in recent
years, tumor node metastasis (TNM) stage and grade, tumor
size, demographics, high rates of recurrence and drug resis-
tance are still widely used to determine the prognosis of can-
cer. Currently, the mechanism of oncogenesis and tumor pro-
gression is still not fully elucidated, which restrict the progno-
sis and metastasis prediction of cancer patients. Many scien-
tists endeavored to cancer diagnosis, prognosis, and treatment
because effective prognostic markers and therapeutic methods
used for tumor therapy and prevention have not been discov-
ered. Some researchers had suggested that identifying ideal
prognostic markers in cancer would be valuable for proper
individual management. Therefore, it is critical to finding a
convenient and effective biomarker with high accuracy prog-
nostic value for cancer patients to improve the survival status.
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As a class of endogenous, evolutionarily conserved small
non-coding RNAs, microRNAs (miRs) have a crucial role that
destabilize the target protein-coding mRNAs or inhibit their
translation by interacting with complementary sequences [3].
Since the discovery of miRs in 1993, growing evidence re-
veals that miRs not only regulate multiple biological process-
es, but also associated with tumor-genetic procedures, such as
adhesion, migration, invasion, angiogenesis and apoptosis [4].
Over the last decade, miRs have gained great attention as
novel biomarkers in tumor prognosis because lots of miRs
are aberrantly expressed in multitudes of cancers [5]. Hence,
more and more researches focus on the miRs as the promising
biomarkers of prognosis.
In recent years, a host of miRs biomarkers have been in-
vestigated in cancer. Among them, miR-9 has been considered
as a candidate prognostic factor in different cancer. Many
observations indicate that the promoted miR-9 level was as-
sociated with worse survival and high risk of cancer metasta-
sis in patients with various carcinomas. However, consensus
has not been reached as to the credibility of miR-9 as a prog-
nostic biomarker in tumor because some other studies present-
ed insignificant or inverse results. Thus, a comprehensive me-
ta analysis of all eligible literatures was conducted to further
assess the clinical feasibility of miR-9 as a novel biomarker for
tumor prognosis.
Material and Methods
The meta analysis was performed totally following the guide
lines of Preferred Reporting Items for Meta analysis of
Observational Studies in Epidemiology group (PRISMA).
Review protocol could be accessed on the site http://www.
crd.york.ac.uk/PROSPERO/ with registration number
CRD42016032714.
Search Strategy and Literature Selection
The Cochrane Library, PubMed (medline), Embase, ISI Web
of Knowledge, ScienceDirect, BioMed Central, Springer to-
gether with three Chinese databases: Weipu, Wanfang and
China National Knowledge Internet (CNKI) databases were
used to conduct a comprehensive computerized literature
search for articles that evaluated the accuracy of miR-9 for
the prognosis and metastasis of cancer. The studies were iden-
tified by using the following keywords in variably combina-
tions: (BmicroRNA-, miRNA-, miR-9,^) and (Bcancer^ or
Btumor^ or Btumour^ or Bneoplasm^) and (Bprognostic^ or
Bprognosis^ or Bsurvival^ or Brecurrence^ or Bmetastasis^).
In addition to the electronic literatures that published between
inception and July 1, 2016, the reference lists of primary stud-
ies were also searched for additional articles.
Inclusion and Exclusion Criteria
Inclusion criteria: 1) Studied the patients with any malignant
tumor; 2) Definite diagnosis confirmed for patients with can-
cer; 3) Studies appraising miR-9 in tissues or serum for can-
cer; 4) Studies with sufficient information to construct the 2 ×
2 contingency Table.
Exclusion criteria: 1) Literatures not pertinent to the miR-9;
2) Studies of non dichotomous miR-9 expression and absence
of survival outcome; 3) Similar studies from the same author
as well as multiple duplicate data in the different works, ex-
cluding earlier and smaller sample data; 4) Animal experi-
ments, case reports, correspondences, reviews, expert opin-
ions, letters, talks, and editorials without original data.
Quality Assessment
As shown in supplementary materials (Checklist S1), all the
eligible articles were systematically assessed based on a crit-
ical review checklist of the Dutch Cochrane Centre proposed
byMOOSE [6]. Major items to be evaluated are as following:
(I) enough information of all types of cancer, (II) clear descrip-
tion of study design, (III) well defined cancer outcomes (IV)
clear description of miR-9 measurement, and (V) sufficient
period of follow-up. Articles should be excluded if the neces-
sary information mentioned above can not be obtained.
Data Extraction
Data was carefully extracted from all eligible studies in dupli-
cate by two independent investigators (YYZ and XC).
Extracted databases were crosschecked between the two au-
thors to rule out any discrepancy. Disagreement was dissolved
by consulting with a third investigator (LML). The following
data for each collected studies were extracted independently: (I)
first author, publication year, study population, and the patients
number; (II) miR-9 assay specimen, miR-9 assessment method;
(III) HR and their 95 % CI of miR-9 value for overall survival,
lymph node metastasis or distant metastasis, with an HR of >1
being associated with a poorer outcome. If only Kaplan–Meier
curves were presented in some articles, the statistical variables
were extracted from the graphical survival plots and an estima-
tion of HR value was then calculated as the previously de-
scribed methods [7, 8]. If any essential information were not
available from the article, best efforts were made to sending a
reminder to the corresponding authors.
Statistical Analysis
All analyses were performed using STATA software, version
12 (Stata Corporation, College Station, TX, USA). The inten-
sity of relationship between the miR-9 expression and out-
come were described as Hazard ratio (HR). All HR and
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95 % confidence interval (CI) were combined from the eligi-
ble articles, and RR was directly considered as HR.
Heterogeneity was quantified with the I2 metric.
Heterogeneity across the eligible studies was also tested using
the Q-test, and the results were considered statistically signif-
icant when P value less than 0.05. A random effects model
was used to evaluate the relationship between miR-9 expres-
sion and survival or metastasis when there was significant
heterogeneity between the included studies (I2 > 30 %).
Since publication bias is critical to the meta analyses, potential
publication bias was assessed by a funnel plot, Begg’s and
Egger’s bias indicator test. Sensitivity analysis was performed
to evaluate the stability of the results.
Results
Screening of the Literature
A total of 1266 studies were retrieved from an initial online
literature search that related to the prognosis and metastasis of
miR-9 and cancer. Based on screening titles and abstracts of
focused articles, 1198 articles were excluded according to the
inclusion and exclusion criteria. The full text of the remaining
65 articles were further identified, 45 studies were excluded
because miR-9 was not treated as a dichotomic variable.
Finally, the remaining 20 publications [9–28] were combined
in the meta analysis and the selection process presented by a
flow chart which is shown in Fig. 1.
Characteristics of the Analyzed Studies
The main characteristics of the analyzed studies were summa-
rized in Table 1. In summary, all the 20 studies were retro-
spective, which dealt with a total of 2441 patients from the
United States, German, France, China, Japan and Korea et al.
The patients were of 14 kinds of carcinomas, including esoph-
ageal cancer, ovarian carcinoma, bladder tumors, glioma, non-
small cell lung cancer, human laryngeal squamous cell carci-
noma, osteosarcoma, adrenocortical cancer, hepatocellular
carcinoma, breast cancer, nasopharyngeal carcinoma, squa-
mous cell carcinoma, leukemia and colorectal cancer.
Different kinds of cancerous tissues were usually examined
to determine miR-9 expression level, most by qRT-PCR
methods, while serum samples were tested in one study. Of
note, the median value was selected as the cut-off value in
most articles.
miR-9 and Overall Survival
A random model was applied to calculate the pooled HR and its
95 % CI due to the presence of heterogeneity among the studies
Fig. 1 Flow chart of the study
selection process
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which involved in overall survival (OS) (I2> 30.0 %). High ex-
pression levels ofmiR-9was demonstrated to significantly predict
unfavorable OS in various human cancers, with the pooled HR of
2.23 (95%CI: 1.56–3.17, P< 0.05) in multivariate analysis stud-
ies (Fig. 2a). Similarly, four univariate analysis studies also predict
the association between high expression levels of miR-9 and OS
(HR: 1.75, 95 % CI: 1.28–2.38, P< 0.05) (Fig. 2b).
Afterwards the subtotal analyses were performed by the
countries, the cancer types, the sample sizes, and the analysis
methods to analyze the possible sources of the heterogeneity
(Table 2). The elevated miR-9 expression predicted a signifi-
cantly worse OS with cancers in China (HR = 2.30; 95 % CI:
1.41–3.75, P < 0.05) and Japan (HR = 3.36; 95 % CI: 1.22–
9.29, P < 0.05) (Fig. 3a). There was significant heterogeneity
across the studies within the subgroups.
For studies evaluating OS in different types of cancer, the
results indicated that elevated miR-9 expression could esti-
mate worse outcome in solid tumor and leukemia, with the
pooled HR of 2.11(95 % CI: 1.44–3.10, P < 0.05), and
3.36(95 % CI: 1.22–9.29, P < 0.05) respectively (Fig. 3b).
Significant heterogeneity existed across the studies within
the subgroups.
The sample size did not alter the predictive value of
miR-9 on the OS for all involved cancers. MiR-9 expres-
sion was found to be correlated with the outcome for sam-
ple sizes greater than or less than 100 subjects (HR = 2.02;
95 % CI: 1.44–2.82, P < 0.05 and HR = 2.70; 95 % CI:
1.13–6.44, P < 0.05, respectively) (Fig. 3c). There was sig-
nificant heterogeneity across the studies within the
subgroups.
Next, we examined the duration of follow-up and found
that the follow-up months (more or less than 60 months) did
not change the result of the estimated HR (HR = 2.32; 95 %
CI: 1.52–3.53, P < 0.05 and HR = 1.68; 95 % CI: 1.14–2.48,
P < 0.05, respectively) (Fig. 3d). There was significant hetero-
geneity across the studies within the subgroups.
Of note, miR-9 detection by qRT-PCRwas demonstrated to
be related with worse outcome in various neoplasms but not
MISH method (HR = 2.54; 95 % CI: 1.72–3.76, P < 0.05 and
HR = 1.07; 95 % CI: 0.45–2.57, P > 0.05, respectively)
(Fig. 3e). Significant heterogeneity was detected within the
subgroups.
Subsequently, we investigated the association between
high level of miR-9 for the disease free survival (DFS),















Hu 2010 USA R EC 172 NA MISH OS/DFS NA HR 150
Maki 2012 Japan R Leukemia 124 NA qRT-PCR OS/RFS NA HR/K-M 17(median)
Li 2013 China R OC 45 I-IV qRT-PCR OS/DFS NA K-M 80
Pignot 2013 France R BLC 72 II-IV qRT-PCR OS/RFS NA K-M 72
Wu 2013 China R Glioma 128 I-IV qRT-PCR OS DM HR/ K-M 60
Xu 2013 China R NSCLC 116 Ia-Ib/IIa-IIb/IIIa qRT-PCR OS/PFS NA HR/ K-M 36
Sugita 2014 Japan R ALL 55 NA qRT-PCR OS/RFS NA HR/ K-M 60
Wu2014 China R LSCC 103 I-IV qRT-PCR OS LNM HR/ K-M 60
Xu 2014 China R OSA 79 I-II/III qRT-PCR OS DM HR/ K-M 60
Song 2014 China R EC 243 I-II/III-IV MISH OS LNM HR/ K-M 60
Fei 2014 China R OSA 118 I–IIA/IIB-III qRT-PCR OS NA K-M 80
Cai 2014 China R HCC 200 I-II/III-IV qRT-PCR OS NA HR/ K-M 60
M.Faria 2015 German R AC 28 I-IV qRT-PCR OS/DFS DM K-M 100
Zhang 2015 TCGA R HCC 327 I-IV qRT-PCR OS NA K-M 166
Gwak 2014 Korea R BC 166 I-II/III qRT-PCR DFS NA HR/ K-M 120
Sun 2015 China R HCC 60 I-II/III-IV qRT-PCR DFS NA HR 20
Lu 2013 China R NC 150 I-IV qRT-PCR NA LNM/DM NA NA
White 2013 USA R ESCC 139 NA MISH NA LNM NA NA
Feng 2014 China R EC 50 I-II/III-IV qRT-PCR NA LNM NA NA
Long 2014 China R CRC 66 I-II/III-IV qRT-PCR NA LNM/ DM NA NA
Study design is described as retrospective (R)
BC, breast cancer, OSA osteosarcoma, NSCLC non-small cell lung cancer, CRC colorectal cancer, HCC hepatocellular carcinoma, BLC bladder cancer,
OC ovarian carcinoma, EC esophageal cancer, LSCC laryngeal squamous cell carcinoma, AC Adrenocortical cancer, ESCC epithelia squamous cell
carcinomas,NC nasopharyngeal carcinoma,MISHmicroRNA in situ hybridization,DM distantMetastasis, LNM LymphNodeMetastasis, TCGATCGA
data portal
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recurrence free survival and progress free survival (RFS and
PFS) of patients with cancer. The random model was used
because significant heterogeneity between these five
multivariate analysis studies (I2 > 30.0 %). Elevated miR-9
expression exhibits no relevance to DFS, with the pooled
HR of 2.54 (95 % CI: 0.92–7.06, P > 0.05). Increased high
Fig. 2 Forrest plots of studies evaluating hazard ratios of high miR-9
expression as compared to low expression. Survival data are reported as
multivariate analysis of OS (a), univariate analysis of OS (b), disease-free
survival (DFS) (c) and relapse-free survival (RFS) or progress-free sur-
vival (PFS) (d)
Table 2 Subgroup analysis of the
pooled HRs of overall survival
with overexpressed miR-9 in pa-
tients with cancer
Subgroup analysis No. of studies No. of patients Pooled HR (95 % CI) Heterogeneity (random)
Random p Value I2(%) p Value
Region
China 8 1032 2.30(1.41,3.75) 0.001 87.1 0.000
Japan 2 179 3.36(1.22,9.29) 0.019 46.3 % 0.172
Other countries 4 599 1.76(0.87,3.53) 0.115 79.2 % 0.002
Sample size
≥100 9 1531 2.02(1.44,2.82) 0.000 72.7 % 0.000
<100 5 279 2.70(1.13,6.44) 0.025 82.5 % 0.000
Type of cancer
Solid cancer 12 1631 2.11(1.44,3.10) 0.000 84.6 % 0.000
Leukemia 2 179 3.36(1.22,9.29) 0.019 46.3 % 0.172
Type of methods
MISH 2 415 1.07(0.45,2.57) 0.875 73 % 0.054
qRT-PCR 12 1621 2.23(1.56,3.17) 0.000 82.1 % 0.000
Follow-up years
≥60 12 1570 2.32(1.51,3.53) 0.000 84 % 0.000
<60 2 240 2.23(1.56,3.17) 0.009 27.9 % 0.239
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miR-9 levels was found moderately correlated with recur-
rence free survival/progress free survival (RFS/PFS)
outcome in three multivariate analysis studies (HR: 2.08,
95 % CI: 1.33–3.27, P < 0.05) (Fig. 2c and d).
Fig. 3 Forest plot showing the subgroup analyses of the pooled HRswith
elevated miR-9 expression in the different types of cancer. Values of p and
I2 and the HRs with their 95 % CI of overall survival (OS) were analyzed
by the factors of Country (a), Cancer type (b), sample size (c), Follow-up
month (d), Method (e)
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Overall, the combined HRs suggested that miR-9 expres-
sion may be an independent prognostic factor for patients with
different kinds of cancer.
miR-9 and Metastasis
We also investigated the association between miR-9 expres-
sion and cancer metastasis and the characteristics of the in-
volved studies were summarized in Tables 3 and 4. When all
the eligible articles were combined with random-effects
models, as shown in Fig. 4, no significant associations were
detected for lymph node metastasis (HR:1.44, 95 % CI: 0.91–
2.26, P > 0.05) and distant metastasis (HR: 2.61, 95 % CI:
0.73–9.25, P > 0.05) respectively.
Publication Bias
Publication bias of the included literatures was assessed by
Begg’s plot and Egger’s tests. The tests revealed that no evi-
dence of publication bias in the analysis of OS (Begg’s P =
1.000 and Egger’s P = 0.614) of all enrolled studies. The
shapes of the funnel plots did not reveal any evidence of
obvious asymmetry (Fig. S1).
Sensitivity Analysis
Sensitivity analysis was conducted to investigate the effect of
any single study on the overall outcomes. No significant
difference was found after remove of any single study, sug-
gesting that the conclusions are stable.
Discussion
With the understanding and knowledge of miRs function
in different kinds of tumor development and progression,
scientists made tremendous contribution to the discovery
that miRs could be a novel potential biomarker for cancer
prognosis. According to the published data, miRs may
potentially regulate up to 30 % of all protein coding genes
and more than 50 % of total miRs are localized on the
fragile region of the cancer genomics [29]. Furthermore,
disparate miRs expression profiling is associated with var-
ious types of neoplasm and these miRs have been proved
to play pivotal roles in tumorigenesis and progression. In
addition, miRs is not vulnerable in easily obtained body
fluid such as serum, plasma, and urine because miRs have
extraordinary stability and tolerance even under severe
physiochemical conditions including extreme temperature,
PH, and freeze–thaw cycles [30, 31]. Collectively, the
advantages mentioned above implied that the application
of miRs as promising biomarkers for cancer prognosis is
viable.
Whether miR-9 is oncogene or tumor suppressor had
been discussed previously but the exact role of miR-9 in
different cancers has not been fully elucidated. Recently,
miR-9 has been discovered to be involved in modulating
Table 3 Characteristics of
studies included in the Lymph
Node metastasis meta-analysis
Study Year No.of patients Method Cut-off miR-9 High miR-9 Low
Metastasis Total Metastasis Total
Wu et al. 2014 103 qRT-PCR Median 22 53 9 50
Song et al. 2014 243 MISH >2 fold 45 82 60 161
Lu et al. 2013 150 qRT-PCR Median 48 65 72 85
White et al. 2013 139 MISH Median 50 63 25 76
Feng et al. 2014 50 qRT-PCR 1.0 9 16 30 34
Long et al. 2014 66 qRT-PCR Score ≥ 4 20 45 3 21
Table 4 Characteristics of




Method Cut-off miR-9 High miR-9 Low
Metastasis Total Metastasis Total
Wu et al. 2013 128 qRT-PCR Median 46 68 12 60
Xu et al. 2014 79 qRT-PCR Median 17 38 2 41
M. Faria et al. 2015 20 qRT-PCR Median 6 9 2 11
Lu et al. 2013 150 qRT-PCR Median 5 111 7 39
Long et al. 2014 66 qRT-PCR Score ≥ 4 18 45 0 21
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cellular processes through regulating the expression of
several target genes such as E-cadherin [32], Foxo3a
[33], NF-κB1 [34] and CXCR4 [35] et al. High expres-
sion levels of miR-9 were observed to promote multiple
cancer cells proliferation, invasion and migration [36, 37],
while knock-down of miR-9 could inhibit cancer cell
growth in vitro [38]. In most clinical studies, as a widely
accepted method in medical science, qRT-PCR was used
to detect the miR-9 expression level. And elevated miR-9
was found in several types of cancers, including breast
cancer, osteosarcoma, hepatocellular carcinoma, bladder
cancer, glioma, laryngeal squamous cell carcinoma, non-
small cell lung cancer, esophageal squamous cell carcino-
ma, et al.
After full texts of eligible literatures were reviewed,
some studies found that a higher expression of miR-9
was significantly associated with worse outcome, such
as overall survival, lymph node metastasis, distant metas-
tasis, vascular involvement and high risk of recurrence.
However, other studies presented insignificant or inverse
results. For instance, Song et al. demonstrated that miR-9
promotes tumor metastasis and related to poor overall
survival in EC, while the following study conducted by
Feng et al. reached an opposite result that low expression
of miR-9 related to lymph node metastasis of EC [16, 27].
These inconsistent results motivated us to perform a meta
analysis to evaluate the relationship between miR-9 ex-
pression and the outcome of patients with various human
cancers. Twenty publications comprising 2441 patients
have been pooled in the present meta analysis, indicating
a statistically significant role of miR-9 on OS (HR: 2.23,
95 % CI: 1.56–3.17, P < 0.05) and RFS/PFS (HR: 2.08,
95 % CI: 1.33–3.27, P < 0.05). Quite a few experts even
recommended that the combination of miR-9 and other
one or two miRs could better predict the prognosis of
tumors. Mounting evidence from primary researches shed
lights upon miR-9, through direct target gene E-cadherin,
which may act as a pro-metastatic miRNA [32]. As shown
in Fig. 4, no association was found between miR-9
expression and metastasis and the contradiction could be
explained by the relative small numbers of eligible articles
or the complicated mechanisms of different tumorigenesis
and progression.
It should be prudentially make the conclusion of the
association with miR-9 and tumors because the meta anal-
ysis has limitations and there are some issues should be
considered. First, the cut-off value of miR-9 expression
varied in different studies and it was arduous to reach a
consensus value. Second, the analysis data derived from
involved literatures should be translated with caution due
to dramatic heterogeneity. As a matter of fact, the large
heterogeneity of meta analysis may due to the differences
in the clinical characteristics of patients (country, tumor
stage etc.), the types of cancer, the types of specimen, the
time of follow-up, and so on. Furthermore, the analysis
result of our studies is not sufficiently persuasive, because
the numbers of prognostic studies for survival and metas-
tasis analyses were relatively small. We need more eligi-
ble clinical studies to confirm the relationship between
miR-9 expression and prognosis of individuals with vari-
ous cancers. The last but not the least, although no pub-
lication bias was detected in the meta analysis, potential
publication bias may exist because desirable results might
be published more easily, which can lead to an over esti-
mation of overall outcome.
In our meta analysis study, even some limitations men-
tioned above, it was preliminarily concluded that promot-
ed miR-9 level is effectively associated with the poor OS
in various kinds of carcinoma. In the future, well de-
signed clinical studies with unified cut-off value and larg-
er samples should be carried out before the practical im-
plementation of miR-9 on the prognosis of neoplasm
patients.
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